This article is a correction to:
Alpha Thalassemia/Intellectual Disability X-Linked Deficiency Sensitizes Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
Tao Hou*
Shun JiangYapeng Wang
Yangchun XieHaixia Zhang
Yeqian Feng
Fang MaJin’an MaXianling Liu
Chunhong Hu- Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
A Corrigendum on
Alpha Thalassemia/Intellectual Disability X-Linked Deficiency Sensitizes Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
By Hou, T., Jiang, S., Wang, Y., Xie, Y., Zhang, H., Feng, Y., Ma, F., Ma, J., Liu, X. and Hu, C. (2021). Front. Oncol. 10:608300. doi: 10.3389/fonc.2020.608300
In the original article, there was a mistake in Figure 4 as published. The first image in the “anti-PD-1” row was incorrect. The corrected Figure 4 appears below.
FIGURE 4
Figure 4 Atrx deficiency sensitizes NSCLC to ICI treatment in orthotopic mouse model. (A) experimental design for establishment of the orthotopic mouse model by intravenous seeding of tumor cells to analyze the tumor burden in vivo. (B) Kaplan-Meier survival curves of mice bearing LLC tumors with and without Atrx deficiency after anti-PD1 or anti-CTLA4 treatment. Neither aCTLA4 (n = 4) nor aPD1 (n = 4) treated mice showed a significant survival difference in Atrx-expression mice, compared with control group (n = 4) (P = 0.9341, 0.9412). Both aCTLA4 (n = 4) and aPD1 (n = 4) treated mice showed a significant survival difference in Atrx-deficient mice, compared with control group (n = 4) (P = 0.006, 0.003). (C) The luciferase signals detected by IVIS in mice bearing LLC generated tumors with and without Atrx deficiency after ICI or isotype antibody treatment. Neither aCTLA4 (n = 4) nor aPD1 (n = 4) treated mice showed a significant signal difference in Atrx-expression mice, compared with control group (n = 4) (P = 0.8521, 0.7644). Both aCTLA4 (n = 4) and aPD1 (n = 4) treated mice showed a significant signal difference in Atrx-deficient mice, compared with control group (n = 4) (P = 0.005, 0.002). **P < 0.01. n.s., not significant.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: lung cancer, immune checkpoint inhibitor, CRISPR, tumor suppressor gene, α-thalassemia/intellectual disability syndrome x-linked
Citation: Hou T, Jiang S, Wang Y, Xie Y, Zhang H, Feng Y, Ma F, Ma J, Liu X and Hu C (2021) Corrigendum: Alpha Thalassemia/Intellectual Disability X-Linked Deficiency Sensitizes Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors. Front. Oncol. 11:705406. doi: 10.3389/fonc.2021.705406
Received: 05 May 2021; Accepted: 12 May 2021;
Published: 02 June 2021.
Edited and reviewed by:
Umberto Malapelle, University of Naples Federico II, ItalyCopyright © 2021 Hou, Jiang, Wang, Xie, Zhang, Feng, Ma, Ma, Liu and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tao Hou, houtao@csu.edu.cn